David J. Schlanger Sells 1,004 Shares of Progyny, Inc. (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) CEO David J. Schlanger sold 1,004 shares of Progyny stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $46.19, for a total transaction of $46,374.76. Following the transaction, the chief executive officer now directly owns 1,004 shares of the company’s stock, valued at $46,374.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

PGNY opened at $44.87 on Thursday. The stock has a market capitalization of $3.91 billion, a PE ratio of 407.91 and a beta of 1.83. Progyny, Inc. has a 1-year low of $17.90 and a 1-year high of $53.48. The firm has a 50-day moving average price of $46.21 and a two-hundred day moving average price of $39.10.

Get Progyny alerts:

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Wednesday, February 24th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.06 by $0.01. Progyny had a net margin of 1.03% and a return on equity of 7.43%. The company had revenue of $100.30 million during the quarter. On average, sell-side analysts expect that Progyny, Inc. will post 0.14 EPS for the current fiscal year.

Several large investors have recently modified their holdings of the company. Clearbridge Investments LLC grew its position in shares of Progyny by 0.4% during the 4th quarter. Clearbridge Investments LLC now owns 2,536,357 shares of the company’s stock worth $107,516,000 after buying an additional 10,135 shares during the period. BlackRock Inc. grew its position in shares of Progyny by 11.8% during the 4th quarter. BlackRock Inc. now owns 2,236,439 shares of the company’s stock worth $94,803,000 after buying an additional 235,442 shares during the period. Brown Advisory Inc. grew its position in shares of Progyny by 0.8% during the 4th quarter. Brown Advisory Inc. now owns 1,326,771 shares of the company’s stock worth $56,242,000 after buying an additional 10,016 shares during the period. GW&K Investment Management LLC grew its position in shares of Progyny by 27.3% during the 4th quarter. GW&K Investment Management LLC now owns 846,802 shares of the company’s stock worth $35,896,000 after buying an additional 181,412 shares during the period. Finally, Bamco Inc. NY grew its position in shares of Progyny by 44.1% during the 4th quarter. Bamco Inc. NY now owns 588,279 shares of the company’s stock worth $24,937,000 after buying an additional 180,000 shares during the period. Institutional investors own 58.54% of the company’s stock.

PGNY has been the subject of several analyst reports. Bank of America raised shares of Progyny from a “neutral” rating to a “buy” rating in a report on Tuesday, March 16th. Zacks Investment Research downgraded shares of Progyny from a “hold” rating to a “sell” rating in a report on Saturday, February 27th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $37.71.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Featured Article: What is insider trading?

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.